To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 19, 2021

Primary Completion Date

August 15, 2024

Study Completion Date

August 15, 2024

Conditions
Myelodysplastic SyndromesMultiple MyelomaAnemia
Interventions
DRUG

INCB000928

INCB000928 will be administered once daily.

Trial Locations (15)

20089

Irccs Istituto Clinico Humanitas, Rozzano

27100

Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo, Pavia

33136

University of Miami, Miami

34232

Florida Cancer Specialists, Sarasota

37232

Vanderbilt University Medical Center, Nashville

40138

L Azienda Ospedaliero-Universitaria Di Bologna Policlinico S. Orsola - Malpighi, Bologna

44093

Centre Hospitalier Universitaire de Nantes (Chu de Nantes) - Hotel-Dieu, Nantes

45219

University of Cincinnati, Cincinnati

48201

Barbara Ann Karmanos Cancer Hospital, Detroit

50134

Azienda Ospedaliero-Universitaria Careggi (Aouc), Florence

69310

Hospices Civils de Lyon Centre Hospitalier Lyon Sud, Pierre-Bénite

70112

Tulane Comprehensive Cancer Center, New Orleans

77030

Md Anderson Cancer Center, Houston

94304

Stanford Cancer Center, Palo Alto

94800

Institut Gustave Roussy, Villejuif

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY